Here's how DOI.ORG makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

DOI . ORG {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Doi.org Make Money
  6. Keywords
  7. Topics
  8. Questions
  9. Schema
  10. Social Networks
  11. External Links
  12. Analytics And Tracking
  13. Libraries
  14. Hosting Providers
  15. CDN Services

We began analyzing https://www.nature.com/articles/nrendo.2016.135, but it redirected us to https://www.nature.com/articles/nrendo.2016.135. The analysis below is for the second page.

Title[redir]:
PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD | Nature Reviews Endocrinology
Description:
Peroxisome proliferator-activated receptors (PPARs) are integrators of both inflammatory and metabolic signalling networks. In this Review, the authors provide a comprehensive overview of how PPARs contribute to the development of metabolic disorders and how pharmacologically targeting these pathways can be used to develop new therapeutics for such diseases. Obesity is a worldwide epidemic that predisposes individuals to cardiometabolic complications, such as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD), which are all related to inappropriate ectopic lipid deposition. Identification of the pathogenic molecular mechanisms and effective therapeutic approaches are highly needed. The peroxisome proliferator-activated receptors (PPARs) modulate several biological processes that are perturbed in obesity, including inflammation, lipid and glucose metabolism and overall energy homeostasis. Here, we review how PPARs regulate the functions of adipose tissues, such as adipogenesis, lipid storage and adaptive thermogenesis, under healthy and pathological conditions. We also discuss the clinical use and mechanism of PPAR agonists in the treatment of obesity comorbidities such as dyslipidaemia, T2DM and NAFLD. First generation PPAR agonists, primarily those acting on PPARγ, are associated with adverse effects that outweigh their clinical benefits, which led to the discontinuation of their development. An improved understanding of the physiological roles of PPARs might, therefore, enable the development of safe, new PPAR agonists with improved therapeutic potential.

Matching Content Categories {📚}

  • Education
  • Health & Fitness
  • Science

Content Management System {📝}

What CMS is doi.org built with?

Custom-built

No common CMS systems were detected on Doi.org, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of doi.org audience?

🏙️ Massive Traffic: 50M - 100M visitors per month


Based on our best estimate, this website will receive around 80,479,999 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Doi.org Make Money? {💸}

We find it hard to spot revenue streams.

Some websites aren't about earning revenue; they're built to connect communities or raise awareness. There are numerous motivations behind creating websites. This might be one of them. Doi.org has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, article, google, scholar, cas, central, peroxisome, proliferatoractivated, receptor, pparγ, cell, pparα, diabetes, activation, liver, adipose, mice, insulin, biol, fatty, expression, lipid, agonist, hepatic, metabolic, tissue, nature, metab, obesity, fat, brown, effects, type, metabolism, patients, nonalcoholic, steatohepatitis, human, disease, med, res, cells, gene, nat, regulation, chem, ppar, adipocyte, pparβδ, fibrosis,

Topics {✒️}

peroxisome proliferator-activated receptor-β/-δ nature portfolio peroxisome proliferator-activated receptor-α peroxisome proliferator-activated receptor-δ permissions reprints privacy policy net/cymabay/media/9af11b3859e3b4fa04eff0f43424ffb5 peroxisome proliferator-activated receptor peroxisome proliferator-activated receptors advertising int/mediacentre/factsheets/fs311/en/ lipoatrophic a-zip/f-1 mice portal pressure fatty acid-induced dysfunction ppar-γ regulates osteoclastogenesis nature 444 nature 485 nature 466 nature 517 nature 502 nature diet-induced hepatic steatosis service pparβ/δ-mediated lipogenesis adipose subtype-selective recruitment author information authors adipocyte-derived th2 cytokines erk/cdk5 axis controls diet-induced obese mice obesity-induced hepatic steatosis amiloride-sensitive channel enac targeting ppar-α expression lipin 1–pgc1α–pparα pathway sirt1-dependent signaling pathway δ promotes reversal ppar-β/-δ palmitate-treated β-cells collecting duct-specific deletion author correspondence nuclear receptor atlas female c57bl/6j mice social media national library macrophage-specific conditional knockouts ppar pan-agonist obesity-linked adipocyte inflammation gov/ct2/show/nct02121717 gov/ct2/show/nct01042106 fatty acid oxidation effective therapeutic approaches

Questions {❓}

  • Adiponectin, driver or passenger on the road to insulin sensitivity?
  • Modulating peroxisome proliferator-activated receptors for therapeutic benefit?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
         description: Peroxisome proliferator-activated receptors (PPARs) are integrators of both inflammatory and metabolic signalling networks. In this Review, the authors provide a comprehensive overview of how PPARs contribute to the development of metabolic disorders and how pharmacologically targeting these pathways can be used to develop new therapeutics for such diseases. Obesity is a worldwide epidemic that predisposes individuals to cardiometabolic complications, such as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD), which are all related to inappropriate ectopic lipid deposition. Identification of the pathogenic molecular mechanisms and effective therapeutic approaches are highly needed. The peroxisome proliferator-activated receptors (PPARs) modulate several biological processes that are perturbed in obesity, including inflammation, lipid and glucose metabolism and overall energy homeostasis. Here, we review how PPARs regulate the functions of adipose tissues, such as adipogenesis, lipid storage and adaptive thermogenesis, under healthy and pathological conditions. We also discuss the clinical use and mechanism of PPAR agonists in the treatment of obesity comorbidities such as dyslipidaemia, T2DM and NAFLD. First generation PPAR agonists, primarily those acting on PPARγ, are associated with adverse effects that outweigh their clinical benefits, which led to the discontinuation of their development. An improved understanding of the physiological roles of PPARs might, therefore, enable the development of safe, new PPAR agonists with improved therapeutic potential.
         datePublished:2016-09-16T00:00:00Z
         dateModified:2016-09-16T00:00:00Z
         pageStart:36
         pageEnd:49
         sameAs:https://doi.org/10.1038/nrendo.2016.135
         keywords:
            Drug development
            Drug therapy
            Dyslipidaemias
            Non-alcoholic fatty liver disease
            Obesity
            Type 2 diabetes
            Medicine/Public Health
            general
            Endocrinology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrendo.2016.135/MediaObjects/41574_2017_Article_BFnrendo2016135_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrendo.2016.135/MediaObjects/41574_2017_Article_BFnrendo2016135_Fig2_HTML.jpg
         isPartOf:
            name:Nature Reviews Endocrinology
            issn:
               1759-5037
               1759-5029
            volumeNumber:13
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Barbara Gross
               affiliation:
                     name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
                     address:
                        name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michal Pawlak
               affiliation:
                     name:International Institute of Molecular and Cell Biology
                     address:
                        name:International Institute of Molecular and Cell Biology, Warsaw, Poland
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Philippe Lefebvre
               affiliation:
                     name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
                     address:
                        name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Bart Staels
               affiliation:
                     name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
                     address:
                        name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD
      description: Peroxisome proliferator-activated receptors (PPARs) are integrators of both inflammatory and metabolic signalling networks. In this Review, the authors provide a comprehensive overview of how PPARs contribute to the development of metabolic disorders and how pharmacologically targeting these pathways can be used to develop new therapeutics for such diseases. Obesity is a worldwide epidemic that predisposes individuals to cardiometabolic complications, such as type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD), which are all related to inappropriate ectopic lipid deposition. Identification of the pathogenic molecular mechanisms and effective therapeutic approaches are highly needed. The peroxisome proliferator-activated receptors (PPARs) modulate several biological processes that are perturbed in obesity, including inflammation, lipid and glucose metabolism and overall energy homeostasis. Here, we review how PPARs regulate the functions of adipose tissues, such as adipogenesis, lipid storage and adaptive thermogenesis, under healthy and pathological conditions. We also discuss the clinical use and mechanism of PPAR agonists in the treatment of obesity comorbidities such as dyslipidaemia, T2DM and NAFLD. First generation PPAR agonists, primarily those acting on PPARγ, are associated with adverse effects that outweigh their clinical benefits, which led to the discontinuation of their development. An improved understanding of the physiological roles of PPARs might, therefore, enable the development of safe, new PPAR agonists with improved therapeutic potential.
      datePublished:2016-09-16T00:00:00Z
      dateModified:2016-09-16T00:00:00Z
      pageStart:36
      pageEnd:49
      sameAs:https://doi.org/10.1038/nrendo.2016.135
      keywords:
         Drug development
         Drug therapy
         Dyslipidaemias
         Non-alcoholic fatty liver disease
         Obesity
         Type 2 diabetes
         Medicine/Public Health
         general
         Endocrinology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrendo.2016.135/MediaObjects/41574_2017_Article_BFnrendo2016135_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fnrendo.2016.135/MediaObjects/41574_2017_Article_BFnrendo2016135_Fig2_HTML.jpg
      isPartOf:
         name:Nature Reviews Endocrinology
         issn:
            1759-5037
            1759-5029
         volumeNumber:13
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Barbara Gross
            affiliation:
                  name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
                  address:
                     name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michal Pawlak
            affiliation:
                  name:International Institute of Molecular and Cell Biology
                  address:
                     name:International Institute of Molecular and Cell Biology, Warsaw, Poland
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Philippe Lefebvre
            affiliation:
                  name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
                  address:
                     name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Bart Staels
            affiliation:
                  name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
                  address:
                     name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature Reviews Endocrinology
      issn:
         1759-5037
         1759-5029
      volumeNumber:13
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
      address:
         name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
         type:PostalAddress
      name:International Institute of Molecular and Cell Biology
      address:
         name:International Institute of Molecular and Cell Biology, Warsaw, Poland
         type:PostalAddress
      name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
      address:
         name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
         type:PostalAddress
      name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
      address:
         name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Barbara Gross
      affiliation:
            name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
            address:
               name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
               type:PostalAddress
            type:Organization
      name:Michal Pawlak
      affiliation:
            name:International Institute of Molecular and Cell Biology
            address:
               name:International Institute of Molecular and Cell Biology, Warsaw, Poland
               type:PostalAddress
            type:Organization
      name:Philippe Lefebvre
      affiliation:
            name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
            address:
               name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
               type:PostalAddress
            type:Organization
      name:Bart Staels
      affiliation:
            name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille
            address:
               name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
      name:International Institute of Molecular and Cell Biology, Warsaw, Poland
      name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
      name:Université de Lille, INSERM, CHU Lille, Institut Pasteur de Lille, Lille, France
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(2)

External Links {🔗}(881)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mx.zoho.eu
  • mx2.zoho.eu
  • mx3.zoho.eu

Name Servers:

  • josh.ns.cloudflare.com
  • zita.ns.cloudflare.com

CDN Services {📦}

  • Crossref

5.79s.